SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is trending amid discussions of its autonomous driving progress and recent fully autonomous testing in Austin, generating excitement and debate within the investment community. Bullish sentiment is fueled by anticipation of future robotaxi revenue and the potential for new all-time highs, though some remain cautious, citing valuation concerns and broader market volatility. Community members are actively discussing the stock's momentum and whether it can sustain its current trajectory.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN is trending due to community discussion around its recent price volatility and potential connection to the broader AI sector. Some investors express concerns about energy consumption and potential risks associated with Chinese ADRs, while others remain optimistic about the company's long-term prospects in AI infrastructure. The community is actively debating IREN's valuation and future contract opportunities, particularly regarding the Sweetwater project.

AMC Robotics Corp. engages in developing and deploying AI-enabled robotics and smart security solutions, especially for warehouse automation, enterprise security, robotics patrol/incident-response and logistics automation. The company is headquartered in New York, NY.

AMC Robotics Corp.

AMCI is trending due to its small float combined with AI/Robotics sector sympathy, reminiscent of previous meme stock runs like $SMX. Community chatter suggests a potential short squeeze and significant price movement, with some traders setting ambitious targets, while others advise caution, emphasizing the importance of trading it as a momentum play rather than a long-term investment.

Lucid Group, Inc. manufactures electric vehicles. It designs, develops, and builds energy storage systems for electric vehicles and supplies automakers with the battery pack system needed to power hybrid, plug-in, and electric vehicles. The company was founded in December 2007 and is headquartered in Newark, CA.

Lucid Group Inc

Lucid Group is trending as investors discuss its financial stability, leadership uncertainty with no permanent CEO, and the potential impact of a possible reverse stock split. The community is weighing the company's technology and product quality against concerns about its capital structure and cash burn. Ongoing debates center on whether Lucid can emulate the success of other meme stocks or if it requires fresh capital or a major partnership to sustain rallies.

Navitas Semiconductor Corp. engages in the development of ultra-efficient gallium nitride (GaN) semiconductors. Its GaN power ICs integrate GaN power with drive, control and protection to enable charging, power density, and energy savings for mobile, consumer, enterprise, eMobility and new energy markets. The company was founded by Daniel Kinzer, Nick Fichtenbaum, Gene Sheridan, and Jason Zhang on August 12, 2020 and is headquartered in Torrance, CA.

Navitas Semiconductor Corp

NVTS is trending amid discussions of potential market manipulation and a recent partnership with GlobalFoundries to accelerate U.S. GaN technology. The community is weighing the impact of this partnership and insider selling, while also speculating on future catalysts such as contract news and potential acquisitions. Some traders are focused on technical analysis, identifying potential breakout points and short squeeze opportunities.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media is trending amid heated online discussions, fueled by controversial comments attributed to Trump regarding the death of a prominent movie director. The community is divided, with some defending his remarks and others expressing outrage, highlighting broader political and cultural fault lines.  Debate includes the company's financials, future prospects, and the broader implications of Trump's influence.

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

$RAGE is trending as the community rallies around the resurgence of OG Memes and the nostalgic vibes of 2021, expressing bullish sentiment after recent market activity. Community members highlight the strong community, ongoing development, and potential exchange listings while emphasizing conviction and active participation. Discussions also focus on the revival of Rage Comics and the project's mission to bring back the spirit of early internet meme culture.

Radiopharm Theranostics Ltd. operates as a pre-clinical and clinical research company. It focuses on the development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical need. The company is founded by Paul A. Hopper in 2021 headquartered Carlton, Australia.

Radiopharm Theranostics Ltd - ADR

RADX is trending due to promising interim data from its brain metastases imaging agent trial, with discussions focused on the potential for a short squeeze and high price targets. The community is closely watching for a break above key resistance levels and anticipating the impact of an upcoming webinar. Some traders are wary of potential dilution and are closely monitoring price action.

Artiva Biotherapeutics, Inc. operates as a biotechnology company for the treatment of hematologic cancers. It offers NK cell therapies for cancer. The company was founded by Thomas J. Farrell in 2019 and is headquartered in San Diego, CA.

Artiva Biotherapeutics Inc

ARTV is trending after receiving FDA Fast Track designation for its AlloNK therapy for refractory rheumatoid arthritis, a significant milestone. Community discussions revolve around the potential for a multi-day run, technical indicators, and potential price targets. The stock is also being compared to other trending tickers, with some cautioning about potential offerings and short attacks.

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Pfizer Inc.

Pfizer Inc

Pfizer is trending due to upcoming investor guidance, with the community actively discussing potential outcomes and impacts on the Covid health sector. A recent FDA statement denying plans for a "black box" warning on COVID vaccines has also influenced sentiment. Investors are weighing Pfizer's future growth prospects amid declining COVID sales and recent acquisitions.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Biotech stocks are a hot-button topic for retail investors on Stocktwits, where over&nbsp;four million users track these companies, hoping to spot the next big therapeutic breakthrough.Two names currently trending in the space are Mainz Biomed, a molecular genetics cancer diagnostic company based in Germany, and Aurinia Pharmaceuticals Inc., a Canadian biopharmaceutical firm focused on autoimmune disease treatments.Over the past three months, Mainz has seen a staggering 2,500% increase in message volume on Stocktwits, while Aurinia’s engagement has grown just 23%.&nbsp;However, Aurinia maintains nearly three times the following of Mainz on the platform.&nbsp;A recent Stocktwits poll of over 1,100 respondents found that 53% believe Mainz offers more upside, compared to 34% favoring Aurinia.<figure class="image"><img style="aspect-ratio:1294/736;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/MYNZ_vs_AUPH_poll_as_of_March_6_43ea585c2e.png" alt="MYNZ vs AUPH poll as of March 6.png" width="1294" height="736"><figcaption>MYNZ vs AUPH poll as of March 6. | source: Stocktwits</figcaption></figure>Maxim Group recently initiated coverage on Mainz with a ‘Buy’ rating and a $14 price target, highlighting its role in the $4 billion colorectal cancer screening market.&nbsp;The firm is optimistic about Mainz’s next-generation test, which uses mRNA biomarkers to improve the detection of pre-cancerous adenomas and potentially enhance colorectal cancer prevention.&nbsp;Mainz is conducting a clinical study on this test, with data expected in the second half of 2025, and plans to finalize protocols for a pivotal U.S. study in 2026.In October, Mainz reported fiscal first-half loss per share had narrowed to $0.48 from $1 a year earlier, with revenue rising to $520,773 from $499,049.&nbsp;The company’s cash and cash equivalents stood at $977,764.Retail traders on Stocktwits have pointed to increasing institutional investment in Mainz, with funds such as Artisan Mid Cap Fund reportedly raising their stakes.&nbsp;<stembedurl>https://stocktwits.com/CarterWood/message/607119518</stembedurl>Some traders speculate that Mainz could see significant catalysts, including an upcoming product launch, a potential partnership, accelerated clinical progress, or an FDA resubmission with fast-track approval.<stembedurl>https://stocktwits.com/FosterD_Nightfall/message/607091090</stembedurl>Aurinia, in contrast, has gained attention for its development of AUR200, a therapy targeting BAFF (B-cell Activating Factor) and APRIL (A Proliferation-Inducing Ligand). The company believes this could become a best-in-class treatment for autoimmune diseases.&nbsp;It has already commercialized Lupkynis, the first FDA-approved oral therapy for adult patients with active lupus nephritis.In its latest financial report, Aurinia posted fourth-quarter earnings of $0.01 per diluted share, a sharp turnaround from a $0.19 loss a year earlier and better than analysts’ projected $0.02 per-share loss.&nbsp;Revenue for the quarter rose to $59.9 million from $45.1 million a year earlier but fell slightly below Wall Street estimates of $60.1 million.&nbsp;For 2025, Aurinia forecasts revenue between $250 million and $260 million, trailing the $274.4 million expected by analysts.Last year, Aurinia said it would <a href="https://stocktwits.com/news-articles/markets/equity/auph-stock-surges-on-insider-buying/cJa2dg8Rin">strengthen</a> its financial position by cutting nearly half its staff to save over $40 million annually.&nbsp;The company also made leadership changes, including CEO Peter Greenleaf’s conditional resignation as a director.&nbsp;As of Dec. 31, 2024, Aurinia held cash, cash equivalents, and investments totaling $358.5 million, up slightly from $350.7 million a year earlier.According to Koyfin data, short interest in Aurinia stood at 7%, compared to 5.1% for Mainz.&nbsp;Over the past year, Aurinia shares have gained more than 44%, though they are down over 9% year-to-date.&nbsp;Mainz, meanwhile, has fallen more than 86% in the past 12 months but has rebounded over 25% since the start of this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Mainz Biomed Vs. Aurinia Pharma: Retail Traders Weigh In On The Better Biotech Bet

Over the past three months, Mainz has seen a staggering 2,500% increase in message volume on Stocktwits, while Aurinia’s engagement has grown just 23%. 

Equity

Mainz Biomed NV is a molecular genetics cancer diagnostic company. The firm is engaged in the developing of market-ready molecular genetic diagnostic solutions for life-threatening conditions. It is involved in the commercializing of its product portfolio in Europe, the United States, and the rest of world. The company was founded on March 08, 2021 and is headquartered in Mainz, Germany.

MYNZ
Mainz Biomed B.V.

Feed

News

Sentiment

Fundamentals

Info

Latest MYNZ News

MYNZMainz Biomed B.V.